NCT04196257 - BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 19, 2022

Primary Completion Date

July 31, 2027

Study Completion Date

October 31, 2027

Conditions

Solid Tumor, AdultCarcinoma, Ovarian EpithelialFallopian Tube NeoplasmsEndometrial CancerPeritoneal CancerSolid Tumor

Interventions

DRUG

BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)

Dose escalation of BP1001-A intravenously (IV), twice weekly for 4 weeks (28-day cycle) for 6 cycles.

DRUG

BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel

Dose expansion of BP1001-A IV twice weekly (Maximum tolerated dose or Maximum admistered dose) plus paclitaxel IV weekly for 4 weeks (28-day cycle) for 6 cycles.

Trial Locations (4)

20910

RECRUITING

Holy Cross Hospital, Silver Spring

48201

RECRUITING

Karmanos Cancer Institute, Detroit

75230

RECRUITING

Mary Crowley Cancer Research, Dallas

77030

RECRUITING

The University of Texas M.D. Anderson Cancer Center, Houston